A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus
Status:
RECRUITING
Trial end date:
2040-12-01
Target enrollment:
Participant gender:
Summary
Primary objective: Safety and tolerability of NKX019, administered after lymphodepletion (LD).
Secondary objectives:
* Assess clinical activity of NKX019 in subjects with systemic lupus erythematosus (SLE) with or without active lupus nephritis (LN)
* Characterize pharmacokinetics (PK) of NKX019
* Characterize immunogenicity of NKX019